September 10th 2020
Omid Hamid, MD, discusses emerging biomarkers in melanoma, data supporting their efficacy and their potential for use in clinical practice, and future directions for research.
September 8th 2020
The FDA has issued an alert that the phase 3 IMpassion131 trial failed to show the effectiveness of atezolizumab plus paclitaxel in treatment-naïve patients with inoperable locally advanced or metastatic triple-negative breast cancer.
September 3rd 2020
Investigators at UPMC Hillman Cancer Center in Pittsburgh, Pennsylvania, have launched a clinical trial to determine the impact on patient outcomes of stopping therapy after 1 year.
September 2nd 2020
Jacob S. Thomas, MD, discusses the pharmacodynamic profile of INT230-6 as well as preliminary safety and efficacy data with the agent in advanced solid tumors.
August 28th 2020
Juanita Lopez, PhD, discusses early findings with RO7198457 in combination with atezolizumab in patients with locally advanced or metastatic malignancies.
August 26th 2020
Gary K. Schwartz, MD, highlights research that is being done with regard to genomic signatures in sarcoma, challenges faced with immunotherapy, and where the field is headed.
The investigational immunotherapeutic ERC1671 in combination with granulocyte-macrophage colony-stimulating factor, cyclophosphamide, and bevacizumab showed promising activity in patients with recurrent glioblastoma.
August 25th 2020
Clinical cancer trials that fail to successfully enroll a racially and ethnically diverse patient population run the risk of leaving critical gaps in understanding regarding the effectiveness of new approaches.
August 24th 2020
The Japan Pharmaceuticals and Medical Devices Agency has approved pembrolizumab for the treatment of patients with radically unresectable, advanced, or recurrent esophageal squamous cell carcinoma whose tumors are PD-L1–positive, and at an additional recommended dosage of 400 mg every 6 weeks as an intravenous infusion across all adult indications.
Spartalizumab in combination with dabrafenib and trametinib failed to meet the primary end point of investigator-assessed progression-free survival in treatment-naïve patients with unresectable or metastatic BRAF V600 mutation–positive cutaneous melanoma.
